Immunotoxins for Treatment of Leukemia and Lymphoma

References

• Irvin J.D., Uckun F.M. Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. Pharmacol. Ther. 1992; 55: 279–302
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Myers D.E. Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies. J. Hematother. 1993; 2: 155–163
   PubMedGoogle Scholar
• Storb R., Deeg H.J., Whitehead J., Appelbaum F., Eleatty P., Bensinger W., Buckner C.D., Clift R., Doney K., Farewell V., Hansen J., Hill K., Lum L., Martin P., McGuffin R., Sanders J., Stewart P., Sullivan K., Witherspoon R., Yee G., Thomas E.D. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host diseases after marrow transplantation for leukemia. N. Engl. J. Med. 1986; 314: 729–735
   PubMed Web of Science ®Google Scholar
• Forman S.J., Blume K.G., Krance R.A., Miner P.J., Metter G.E., Hill L.R., O'Donnell M.R., Nadamanee A.P., Snyder D.S. A prospective randomized study of acute graft-versus-host diseases in 107 patients with leukemia: Methotrexate/prednisone versus cyclosporine/prednisone. Transplant. Proc. 1987; 19: 2605–2607
   PubMed Web of Science ®Google Scholar
• Trigg M.E., Billing R., Sondel P.M., Exten M.E., Hong R., Bozdech M.J., Horowitz S.D., Finlay J.L., Moen R., Longo W., Erickson C., Peterson A. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. Cancer Treat. Rep. 1985; 69: 377–386
   PubMedGoogle Scholar
• Franceschini F., Butturini A., Gale R.P. Clinical trials of T cell depletion in bone marrow transplantation. Progress in Bone Marrow Transplantation, R.P. Gale, R. Champlin. Alan R. Liss, NY 1987; 323–335
   Google Scholar
• Blazar B.R., Filipovich A.H., Kersey J.H., Uckun F.M., Ramsay N.K.C., McGlave P.B., Vallera D.A. T cell depletion of donor marrow grafts: effects on graft-versus-host disease and engraftment. Progress in Bone Marrow Transplantation, R.P. Gale, R. Champlin. Alan R. Liss, NY 1987; 381–397
   Google Scholar
• Filipovich A.H., Vallera D.A., Youle R.J., Haake R., Blazar B., Arthur D., Neville D.M., Jr, Ramsay N.K.C., McClave P., Kersey J.H. Graft-versus-host disease prevention in allogeneic hone marrow transplantation for histocompatibie siblings. A pilot study wing immunotoxins for T cell depletion of donor bone marrow. Transplantation 1987; 44: 62–69
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Kersey J.H., Vallera D.A., Ledbelter J.A., Weisdorf D., Myers D.E., Hake R., Ramsay N.K.C. Autologous hone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733
   PubMed Web of Science ®Google Scholar
• Greaves M.F. Differentiation linked leukemogenesis in lymphocytes. Science 1986; 234: 697–704
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Haissig S., Ledbetter J.A., Fidler P., Myers D.E., Kuebelbeck V., Weisdorf D., Gajl-Peczalska K., Kersey J.H., Ramsay N.K. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using auto-grafts depleted of CD 19+ B-cell precursors by an anti-CD 19 pan B-cell immunotoxin containing pokeweed antiviral protein. Blood, 79: 3369–3379
   PubMed Web of Science ®Google Scholar
• Uckun F.M. Regulation of human B-cell ontogeny. Blood 1990; 76: 1908–1923
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Jaszcz W., Ambrus J.L., Fauci A.S., Gajl-Peczalska K.J., Song C.W., Wick M.R., Myers D.E., Waddick K.G., Ledbetter J.A. Detailed studies on expression and function of CD 19 surface determinant using B43 monoclonal antibody. Blood 1988; 71: 13–29
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Myers D.E., Jaszcz W., Haissig S., Gajl-Peczalska K., Ledbetter J.A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990; 76: 2449–2456
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Gajl-Peczalska K.J., Kersey J.H., Houston L.L., Vallera D.A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. Exp. Med. 1986; 163: 347–368
   PubMed Web of Science ®Google Scholar
• Jansen B., Uckun F.M., Jaszcz W.B., Kersey J.H. Establishment of a human t(4:11) leukemia in SCID mice and successful treatment using anti-CD 19 (B43)-pokeweed antiviral protein immunotoxin. Cancer Res. 1992; 52: 406–412
   PubMed Web of Science ®Google Scholar
• Jansen B., Kersey J.H., Jaszcz W.B., Gunther R., Nguyen D., Chelstrom L.M., Uckun F.M. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD 19)-poke-weed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 1992; 7: 290–297
   Web of Science ®Google Scholar
• Uckun F.M., Manivel C., Arthur D., Chelstrom L., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Gunther R. In vivo efficacy of 843 (anti-CD 19) pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 79: 2201–2214
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Gunther R. Effective immunochemotherapy of CALLA+Cμ+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using 843 (anti-CD 19) pokeweed antiviral protein (PAP) immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116–3129
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Ramakrishnan S., Houston L.L. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B cell specific immunotoxin containing pokeweed antiviral protein. Cancer Res. 1985; 45: 69–75
   PubMed Web of Science ®Google Scholar
• Nadler L., Breitmeyer J., Coral F., Spector N., Schlosman S. Anti-B4 blocked ricin immunotherapy for patients with B cell malignancies. Proceedings of the 2nd International Symposium on Immunotoxins 1990; 58
   Google Scholar
• Grossbard M.L., Nadler L.M. Immunotoxin therapy of malignancy. Important Advances in Oncology, V.T. De Vita, S. Heilman, S.A. Rosenberg. Lippincott, Philadelphia 1992; 112–136
   Google Scholar
• Vitetta E.S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J.W., Thorpe P.E. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991; 51: 4052–4058
   PubMed Web of Science ®Google Scholar
• Laurent G., Frankel A.E., Hertler A.A. Treatment of leukemia patients with T 101 ricin A chain immunotoxins. Cancer Treat. Rep. 1988; 37: 483–491
   Google Scholar
• Hertler A.A., Schlossman D.M., Borowitz M.J., Laurent G., Jansen F.K., Schmidt C., Frankel A.E. A phase I study of T 101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J. Biol. Resp. Mod. 1988; 7: 97–113
   PubMedGoogle Scholar
• Le Maistre C.F., Rosen S., Frankel A., Kornfeld S., Saria E., Meneghetti C., Drajesk J., Fishwild D., Scannon P.J., Byers V.S. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991; 78: 37–46
   Google Scholar
• Youle R.J., Greenfield L., Johnson V.G. Genetic engineering of immunotoxins. Immunotoxins, A.E. Frankel. Kluwer Academic Publishers, Boston 1988; 113–122
   Google Scholar
• Firz Gerald D.J., Willingham M.C., Pastan I. Pseudomonas exotoxin—Immunotoxins. Immunotoxins, A.E. Frankel. Kluwer Academic Publishers, Boston 1988; 161–173
   Google Scholar
• Youle R.J., Neville D.M., Jr. Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the rich B subunit demonstrated by reconstitution. J. Biol. Chem. 1982; 257: 1598–1601
   PubMed Web of Science ®Google Scholar
• Youle R.J., Murray G.J., Neville D.M., Jr. Studies on the galactose-binding site of ricin and the hybrid toxin Man6P-ricin. Cell 1981; 23: 551–559
   PubMed Web of Science ®Google Scholar
• Vitetta E.S. Synergy between immunotoxins prepared with native ricin A chains and chemically-modified ricin B chains. J. Immunol. 1986; 136: 1880–1887
   PubMed Web of Science ®Google Scholar
• Colombatti M., Greenfield L., Youle R.J. Cloned fragment of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry. J. Biol. Chem. 1986; 261: 3030–3035
   PubMed Web of Science ®Google Scholar
• Greenfield L., Johnson V.G., Youle R.J. Mutations in Diphtheria Toxin Separate Binding From Entry and Amplify Immunotoxin Selectivity. Science 1987; 238: 536–539
   PubMed Web of Science ®Google Scholar
• Waldmann T.A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232: 727–732
   PubMed Web of Science ®Google Scholar
• Murphy J.R. Diphtheria-related peptide hormone gene fusions: A molecular genetic approach to chimeric toxin development. Immunotoxins, A.E. Frankel. Kluwer Academic Publishers, Boston 1988; 123–140
   Google Scholar
• Le Maistre C.F., Meneghetti C., Rosenblum M., Reuben J., Parker K., Shaw J., Deisseroth A., Woodworth T., Parkinson D.R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486L-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547–2554
   PubMed Web of Science ®Google Scholar
• Kuzel T., Rosen S., Gordon L., Winter J., Samuelson E., Kaul K., Roenigk H., Nylen P., Woodworth T. Safety and biologic effects of DAB486L-2 in IL-2 receptor expressing malignancies. Proc. Am. Assoc. Cancer Res. 1992; 33: 1358
   Google Scholar
• Foss F., Borkowski T., Tompkins A., Gilliom M., Cooper M., Udey M., Stetler-Stevenson M., Jaffe E., Woodworth T., Sausville E. Pilot phase II study of a DAB486L-2 fusion toxin in cutaneous T-cell lymphoma. Proc. Am. Assoc. Cancer Rex 1993; 34: 1236
   Google Scholar
• Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/function analysis of interleukin-2-toxin (DAB486L-2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 1990; 265: 11885–11889
   PubMed Web of Science ®Google Scholar
• Bacha P., Parker K., Nylen P., Nichols J.C., Woodworth T.W. and the DAB486L-2 Lymphoma Study Group. 1993 DAB486L-2 fusion toxin evaluation in lymphomaclinical trials. Proc. Am. Assoc. Cancer Res., 34: 1237
   Google Scholar
• Kreitrnan R.J., Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leukemia Lymph. 1994; 13: 1–10
   Web of Science ®Google Scholar
• Chaudhary V.K., Queen C., Junghans R.P., Waldmann T.A., FitzGerald D.J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989; 339: 394–397
   PubMed Web of Science ®Google Scholar
• Batra J.K., Fitz Gerald D., Gately M., Chaudhary V.K., Pastan I. Anti-Tac(Fv)-PE40: a single chain antibody Pseudomonas fusioin protein directed at interleukin 2 receptor bearing cells. J. Biol. Chem. 1990; 265: 15198–15202
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Waldmann T., Willingham M.C., Fitz Gerald D.J., Pastan I. The recombinant im-munotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. Proc. Natl. Acad. Sci. USA 1990; 87: 8291–8295
   PubMed Web of Science ®Google Scholar
• Yagura H., Tamaki T., Furitsu T., Tomiyama Y., Nishiura T., Tominaga N., Katagiri S., Yonezawa T., Tarui S. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization. Blut 1990; 60: 181–186
   PubMedGoogle Scholar
• Kodaka T., Uchiyama T., Ishikawa T., Kamio M., Onishi R., Itoh K., Hori T., Uchino H., Tsudo M., Araki K. Interleukin-2 recteptor β-chain (p70–75) expressed on leukemic cells from adult T cell leukemia patients. Jpn. J. Cancer Res. 1990; 81: 902–908
   PubMedGoogle Scholar
• Kreitman R.J., Bailon P., Chaudhary V.K., Fitz Gerald D.J., Pastan I. Recombinant immunotoxins containing anti -Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 1991; 83: 426–434
   Google Scholar
• Hale G., Dyer M J.S., Clark M.R., Phillips J.M., Marcus R., Riechmann L., Winter G., Waldmann H. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-IH. Lancet 1988; 2: 1394–1399
   PubMed Web of Science ®Google Scholar
• Sehon A.H. Suppression of IgE antibody responses with tolerogenic conjugates of allergens and haptens. Prog. Allergy 1982; 32: 161–202
   PubMedGoogle Scholar
• Rybak S.M., Saxena S.K., Ackerman E.J., Youle R.J. Cytotoxic Potential of Ribonuclease and Ribonuclease Hybrid Proteins. J. Biol. Chem. 1991; 266: 21202–21207
   PubMed Web of Science ®Google Scholar
• Youle R.J., Newton D., Wu Y.N., Gadina M., Rybak S.M. Cytotoxic ribonucleases and chimeras in cancer therapy. Crit. Rev. Titer. Drug Carrier Syst. 1993; 10: 1–28
   PubMed Web of Science ®Google Scholar